Skip to content
Open access · CC-BY via OpenAlex

Plasma Biomarkers of Alzheimer's Disease and Neurodegeneration According to Sociodemographic Characteristics and Chronic Health Conditions

Heming Zheng, Zhiyong Wu, Michelle M. Mielke, Anne M. Murray, Joanne L. Ryan

The Journal of Prevention of Alzheimer s Disease · 2024 · ▲ 30 citations

Abstract

Ultrasensitive assays have been developed which enable biomarkers of Alzheimer's disease pathology and neurodegeneration to be measured in blood. These biomarkers can aid in diagnosis, and have been used to predict risk of cognitive decline and Alzheimer's disease. The ease and cost-effectiveness of blood collections means that these biomarkers could be applied more broadly in population-based screening, however it is critical to first understand what other factors could affect blood biomarker levels. The aim of this review was to determine the extent that sociodemographic, lifestyle and health factors have been associated with blood biomarkers of Alzheimer's disease and neuropathology. Of the 32 studies included in this review, all but one measured biomarker levels in plasma, and age and sex were the most commonly investigated factors. The most consistent significant findings were a positive association between age and neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP), and females had higher GFAP than men. Apolipoprotein ε4 allele carriers had lower Aβ42 and Aβ42/40 ratio. Body mass index was negatively associated with GFAP and NfL, and chronic kidney disease with higher levels of all biomarkers. Too few studies have investigated other chronic health conditions and this requires further investigation. Given the potential for plasma biomarkers to enhance Alzheimer's disease diagnosis in primary care, it is important to understand how to interpret the biomarkers in light of factors that physiologically impact blood biomarker levels. This information will be critical for the establishment of reference ranges and thus the correct interpretation of these biomarkers in clinical screening.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.14283/jpad.2024.142
Canonical
link ↗
Fetched
2026-10-17 MST

Cite this

APA
Zheng, H., Wu, Z., Mielke, M.M., Murray, A.M., &amp; Ryan, J.L. (2024). Plasma Biomarkers of Alzheimer's Disease and Neurodegeneration According to Sociodemographic Characteristics and Chronic Health Conditions. <em>The Journal of Prevention of Alzheimer s Disease</em>. https://doi.org/10.14283/jpad.2024.142
Vancouver
Zheng H, Wu Z, Mielke MM, Murray AM, Ryan JL. Plasma Biomarkers of Alzheimer's Disease and Neurodegeneration According to Sociodemographic Characteristics and Chronic Health Conditions. The Journal of Prevention of Alzheimer s Disease. 2024. doi:10.14283/jpad.2024.142.
BibTeX
@article{heming2024Plasma, title = {Plasma Biomarkers of Alzheimer's Disease and Neurodegeneration According to Sociodemographic Characteristics and Chronic Health Conditions}, author = {Heming Zheng and Zhiyong Wu and Michelle M. Mielke and Anne M. Murray and Joanne L. Ryan}, journal = {The Journal of Prevention of Alzheimer s Disease}, year = {2024}, doi = {10.14283/jpad.2024.142}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings